Accueil   Agenda - News   Toutes les news MaaT Pharma receives three patents covering its biotherapeutic microbiome restoration platform

MaaT Pharma receives three patents covering its biotherapeutic microbiome restoration platform

 

  • First patents to cover the fundamental processes for accessing the human gut microbiome as biotherapeutics.
  • MaaT Pharma’s microbiome sample collection and administration devices receive CE mark for use in collecting and administrating gut-derived samples as biotherapeutics to patients

 

Lyon, France, May 22, 2019 – MaaT Pharma announced today that the Institut National de la Propriété Industrielle (INPI), the French Patent Office, has issued three new patents to the company covering its sample collection device and the overall processes associated with obtaining, processing, storing and administering human gut samples, ensuring that the highest quality of microbiota is present in MaaT Pharma’s biologic drugs. In addition, the patents cover an innovative process to freeze-dry samples preserving the viability and taxonomic profile of the microbiome and enabling the development of an oral formulation. These patented processes developed under a five year research collaboration with the French National Institute for Agricultural Research (INRA) are a fundamental part of MaaT Pharma’s integrated Microbiome Restoration Biotherapeutic (MMRB) platform and have a broad applicability in treating dysbiosis-related diseases.

 

Lire le communiqué de presse

En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de cookies pour vous proposer des services et offres adaptés à vos centres d'intérêt. En savoir plus... Fermer